Bristol Myers Squibb presents new interim pooled long-term safety and metabolic outcome data from the EMERGENT program evaluating KarXT in schizophrenia at the 2024 Annual Meeting of the International...

Related Keywords

Roland Chen , Bristol Myers Squibb , Neuroscience Development At Bristol Myers Squibb , International Society , Senior Vice President , Neuroscience Development , Bristol Myers , Markets ,